一种专为纯合子家族性高胆固醇血症患者量身定制的一流药物洛美他派，正给他们带来好消息。 - Suppr

A First-in-Class Drug, Lomitapide, Tailored to Patients with Homozygous Familial Hypercholesterolemia is Just about Meeting with Good News to Them.

作者信息

Yoshida Hiroshi

机构信息

Department of Laboratory Medicine, Jikei University Kashiwa Hospital.

出版信息

J Atheroscler Thromb. 2017 Apr 3;24(4):390-392. doi: 10.5551/jat.ED069. Epub 2017 Feb 24.

DOI:10.5551/jat.ED069

PMID:28239069

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5392476/

Abstract

摘要

相似文献

A First-in-Class Drug, Lomitapide, Tailored to Patients with Homozygous Familial Hypercholesterolemia is Just about Meeting with Good News to Them.

J Atheroscler Thromb. 2017 Apr 3;24(4):390-392. doi: 10.5551/jat.ED069. Epub 2017 Feb 24.

The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.

Eur J Prev Cardiol. 2017 Nov;24(17):1843-1850. doi: 10.1177/2047487317730473. Epub 2017 Sep 19.

Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.

Circulation. 2014 Mar 4;129(9):1022-32. doi: 10.1161/CIRCULATIONAHA.113.001292.

Case report: The efficacy and safety of lomitapide in a homozygous familial hypercholesterolemic child.

J Clin Lipidol. 2019 May-Jun;13(3):397-401. doi: 10.1016/j.jacl.2019.03.001. Epub 2019 Mar 11.

LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design.

J Clin Lipidol. 2016 Mar-Apr;10(2):273-82. doi: 10.1016/j.jacl.2015.11.011. Epub 2015 Dec 1.

Lomitapide for use in patients with homozygous familial hypercholesterolemia: a narrative review.

Expert Rev Clin Pharmacol. 2016;9(5):655-63. doi: 10.1586/17512433.2016.1162095. Epub 2016 Mar 21.

Lomitapide for the management of homozygous familial hypercholesterolemia.

Rev Cardiovasc Med. 2014;15(2):109-18. doi: 10.3909/ricm0735.

Gradual dose Titration of Lomitapide may Prevent Therapeutic Delays in Patients with Homozygous Familial Hypercholesterolemia.

J Atheroscler Thromb. 2023 Feb 1;30(2):203-205. doi: 10.5551/jat.LE003. Epub 2022 Jun 23.

Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia.

Am J Health Syst Pharm. 2014 Jun 15;71(12):1001-8. doi: 10.2146/ajhp130592.

Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience.

J Cardiovasc Med (Hagerstown). 2018 Mar;19(3):83-90. doi: 10.2459/JCM.0000000000000620.

本文引用的文献

Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia.

J Atheroscler Thromb. 2017 Apr 3;24(4):402-411. doi: 10.5551/jat.38216. Epub 2017 Feb 2.

Monthly PCSK9 inhibitors: The CHOICE for prolonged duration of effect.

Atherosclerosis. 2016 Nov;254:300-302. doi: 10.1016/j.atherosclerosis.2016.09.013. Epub 2016 Oct 13.

Management of homozygous familial hypercholesterolemia in real-world clinical practice: A report of 7 Italian patients treated in Rome with lomitapide and lipoprotein apheresis.

J Clin Lipidol. 2016 Jul-Aug;10(4):782-789. doi: 10.1016/j.jacl.2016.02.009. Epub 2016 Feb 27.

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.

JAMA. 2016 Aug 16;316(7):743-53. doi: 10.1001/jama.2016.11004.

Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan.

Atherosclerosis. 2016 Aug;251:248-254. doi: 10.1016/j.atherosclerosis.2016.07.001. Epub 2016 Jul 4.

MTP Gene Variants and Response to Lomitapide in Patients with Homozygous Familial Hypercholesterolemia.

J Atheroscler Thromb. 2016 Jul 1;23(7):878-83. doi: 10.5551/jat.34777. Epub 2016 May 10.

Recent advances in the pharmacological management of hypercholesterolaemia.

Lancet Diabetes Endocrinol. 2016 May;4(5):436-46. doi: 10.1016/S2213-8587(16)00074-7. Epub 2016 Mar 21.

Lipoprotein (a): Coming of Age at Last.

J Lipid Res. 2016 Mar;57(3):336-9. doi: 10.1194/jlr.E066985. Epub 2016 Feb 2.

The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association.

Circulation. 2015 Dec 1;132(22):2167-92. doi: 10.1161/CIR.0000000000000297. Epub 2015 Oct 28.

Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study.

Am Heart J. 2014 Dec;168(6):878-83.e1. doi: 10.1016/j.ahj.2014.08.007. Epub 2014 Sep 16.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

A First-in-Class Drug, Lomitapide, Tailored to Patients with Homozygous Familial Hypercholesterolemia is Just about Meeting with Good News to Them.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献